Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Operations: 2011-2024

Historic Cash from Operations for Abeona Therapeutics (ABEO) over the last 14 years, with Dec 2024 value amounting to -$56.0 million.

  • Abeona Therapeutics' Cash from Operations fell 73.18% to -$21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.9 million, marking a year-over-year decrease of 53.89%. This contributed to the annual value of -$56.0 million for FY2024, which is 51.36% down from last year.
  • According to the latest figures from FY2024, Abeona Therapeutics' Cash from Operations is -$56.0 million, which was down 51.36% from -$37.0 million recorded in FY2023.
  • In the past 5 years, Abeona Therapeutics' Cash from Operations ranged from a high of -$35.0 million in FY2020 and a low of -$65.7 million during FY2021.
  • Over the past 3 years, Abeona Therapeutics' median Cash from Operations value was -$43.5 million (recorded in 2022), while the average stood at -$45.5 million.
  • In the last 5 years, Abeona Therapeutics' Cash from Operations soared by 44.26% in 2020 and then slumped by 87.51% in 2021.
  • Abeona Therapeutics' Cash from Operations (Yearly) stood at -$35.0 million in 2020, then plummeted by 87.51% to -$65.7 million in 2021, then spiked by 33.78% to -$43.5 million in 2022, then increased by 14.89% to -$37.0 million in 2023, then slumped by 51.36% to -$56.0 million in 2024.